LONDON, 26 March 2026 – Baker Botts L.L.P., a leading international energy, technology, and life sciences law firm, advised Hansa Biopharma AB (Nasdaq Stockholm: HNSA) on its U.S.$30 million cross-border convertible note financing with certain funds managed by Athyrium Capital Management, drawing on the firm’s expertise in complex international capital markets transactions in the life sciences sector.

The financing, comprising unsecured convertible senior notes maturing in 2031, was structured at a premium to market and provides Hansa Biopharma with additional capital to advance its pipeline, extend its runway into mid-2027, and support its planned U.S. launch of imlifidase, subject to approval. 

Baker Botts advised the company on the U.S. securities law aspects of the transaction. The team included partner Patrick Lyons and senior associate Amy Rees in London, and partner Geoff Newton in Houston. 

The firm worked alongside Advokatfirman Vinge KB, which acted as Swedish counsel to the company. Other advisors to the transaction included Paul Hastings LLP and Mannheimer Swartling Advokatbyrå AB for Athyrium. 

ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm whose lawyers practice throughout a network of offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the energy, technology and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.